Investigation of Aromatase in Endometrial Hyperplasia in the Polycystic Ovary Syndrome

Pan-Lin Zhao,Qiu-Fang Zhang,Li-Ying Yan,Shuo Huang,Yuan Chen
2014-01-01
Abstract:Polycystic ovary syndrome (PCOS) is one of the most common diseases in gynecology and endocrinology clinic (Lin et al., 2014; Tokmak et al., 2014). Its main manifestations are menstrual disorder, continuous anovulation, hyperandrogenism and polycystic ovary etc. As PCOS patients suffer from long-term anovulation and the endometrium lacks the effect of progestin due to longterm exposure to estrogen, the morbidity of endometrial hyperplasia and endometrial cancer increases significantly, up to 23% (Park et al., 2011). The abnormality of steroid hormone is one of the manifestations of PCOS. Therefore, aromatase, the key rate-limiting enzyme in the synthesis of steroid hormone, becomes a focus of numerous research. Aromatase cytochrome P450 (P450arom, CYP) encoding by CYP19 gene is a rate-limiting enzyme in the final step of the estrogen biosynthesis related to estrogendependent diseases, such as breast cancer, hysteromyoma, endometriosis and endometrial cancer (Sen et al., 2012). The promoters of CYP19 gene are tissue-specific (Bulun et al., 2004). The promoter II and promoter I.3 are used in human malignant endometrial tumors (Bulun et al., 1994). In 1982, Tseng firstly reported the existance of the aromatase in endometrial tissues (Tseng et al., 1982). In 1995, Watanabe reported that there was no expression
What problem does this paper attempt to address?